Aardvark is also developing ARD-201, a fixed-dose combination of ARD-101 with a DPP-4 inhibitor, with a goal of addressing some of the limitations of currently marketed GLP-1 therapies for the ...

Aardvark Therapeutics reports 2025 Q1 financial results; Phase 3 trial data for ARD-101 expected 2026. Quiver AI Summary. Aardvark Therapeutics, Inc. announced progress in its Phase 3 HERO trial ...

In February 2025, Aardvark successfully completed its initial public offering (IPO), raising $97.9 million in gross proceeds. After deducting underwriting discounts, commissions, and offering ...

Aardvark Therapeutics, Inc. Condensed Consolidated Balance Sheets (in thousands, except share amounts) March 31, December 31, 2025: 2024 (unaudited) Assets: Current assets: Cash and cash equivalents $ ...

Aardvark has been developed by researchers from Cambridge University supported by the Alan Turing Institute, Microsoft Research and the European Centre for Medium Range Weather Forecasting.. Detailed ...

“Aardvark reimagines current weather prediction methods offering the potential to make weather forecasts faster, cheaper, more flexible and more accurate than ever before, helping to transform weather ...

Mar 24, 2025 12:30:00 Aardvark Weather, an AI weather forecasting system that uses AI and runs on a standard desktop PC, is much faster with thousands of times less computing power than ...

Aardvark late Wednesday priced 5.88 million shares at $16 each, which was the low end of the price range set in preliminary IPO terms last week. Those shares will trade on the Nasdaq under the ...

Obesity-focused Aardvark Therapeutics is heading to the Nasdaq this morning in an IPO that matched the low end of its expectations.. The company’s 5.9 million shares will be offered at $16 ...

Potential Positives. Aardvark Therapeutics successfully priced its initial public offering at $16.00 per share, raising approximately $94.2 million in gross proceeds, which will provide ...

SAN DIEGO, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (“Aardvark”) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule ...

Aardvark Therapeutics plans a $100M IPO for metabolic treatments, targeting rare Prader-Willi syndrome with a potential market cap of $200-300M. Read the full AARD IPO preview here.